Viela Bio, Inc. |
72677055101 |
UPLIZNA™ (inebilizumab-cdon), Carton containing three 100 mg /10 mL single-dose vials |
2020-07-13 |
131000.0000 |
Uplizna is the first and only B-cell depleter approved for the treatment adult patients with AQP4+ neuromyelitis optica spectrum disorder (NMOSD). Viela’s approach to marketing includes a focus on educating healthcare professionals, primarily neurologists, about the devastating effects of this rare disease and providing information about the efficacy, safety and dosing of Uplizna. Marketing includes dissemination of print materials, digital advertising, in-person presentations and virtual engagements. In addition to healthcare professionals, Viela also provides educational resources and support to the patient community in collaboration with advocacy organizations.
Viela’s approach to pricing innovative therapies is driven by the value a drug brings to customers. Leading up to FDA approval, the company engaged with key stakeholders—including patients, payers and physicians—to better understand the value this medicine could bring to people affected by NMOSD, who despite recent innovation, have limited treatment options. |
None |
10000 |
1 |
None |
None |
None |
None |
None |
None |
None |
ViiV Healthcare |
49702025018 |
RUKOBIA (fostemsavir) 600mg extended-release tablets |
2020-07-22 |
7650.0000 |
None |
1 |
9300 |
1 |
1 |
None |
None |
None |
None |
Regarding Marketing/Pricing Plan Description, ViiV has not released RUKOBIA's marketing or pricing plan information in the public domain and is limiting its response to that which is publicly available pursuant to California Code of Regulations, Title 22, Division 7, Chapter 9.5 Section 96076(c).
RUKOBIA is a novel attachment inhibitor for the treatment of HIV-1 infection indicated for use in combination with other antiretroviral (ARV) therapies in heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection, failing their current antiretroviral regimen due to resistance, intolerance or safety considerations. The estimated HTE population who are unable to form a suppressive regimen and potentially eligible for treatment with RUKOBIA is approximately 9,300 for the US. This is based on the number of people living with HIV according to the Centers for Disease Control and Prevention (CDC) and a projection for the heavily treatment-experienced adult population who are unable to form a suppressive regimen.
RUKOBIA was granted breakthrough therapy designation and priority review by the Food And Drug Administration.
Note on Acquisition Fields: ViiV acquired fostemsavir as an investigational asset from Bristol Myers Squibb and completed development of the product. Accordingly, Rukobia was not an approved prescription drug at the time ViiV acquired it. Therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT. |
None |